The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2023 | FcRH5 & GPRC5D bispecific antibodies: antigen targets beyond BCMA for multiple myeloma
Carlyn Tan, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, briefly discusses the ongoing research on bispecific antibodies for multiple myeloma, focusing on alternative antigen targets beyond BCMA. Dr Tan comments on two promising drugs: cevostamab which targets FcRH5, and talquetamab, which targets GPRC5D. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen – research funding, advisory board
Sanofi – advisory board
Takeda – research funding
